Pharmacogenomic Effect/ADR for Tamoxifen (DBSNPE005874)

Identifier
DBSNPE005874
Drug
DB00675 (Tamoxifen)
Interacting Gene/Enzyme
Cytochrome P450 2D6
Gene Name
CYP2D6
UniProt ID
P10635
Defining Change(s)
100C>Trs1065852
-1426C>TNot Available
variable number of A’s in the region -1258 to -1237aNot Available
-1235A>GNot Available
-1000G>ANot Available
1039C>TNot Available
1661G>CNot Available
gene conversion to CYP2D7 in exon 9Not Available
4180G>CNot Available
Allele Name
CYP2D6*36
Genotype(s)
Not Available
Type(s)
Effect Inferred
Groups
Non-functional CYP2D6
Description
Poor response to drug treatment, shorter time to relapse
References
  1. Gaedigk A, Bradford LD, Alander SW, Leeder JS: CYP2D6*36 gene arrangements within the cyp2d6 locus: association of CYP2D6*36 with poor metabolizer status. Drug Metab Dispos. 2006 Apr;34(4):563-9. Epub 2006 Jan 13. [PubMed:16415111]
  2. Sakuyama K, Sasaki T, Ujiie S, Obata K, Mizugaki M, Ishikawa M, Hiratsuka M: Functional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10, 14A-B, 18, 27, 36, 39, 47-51, 53-55, and 57). Drug Metab Dispos. 2008 Dec;36(12):2460-7. doi: 10.1124/dmd.108.023242. Epub 2008 Sep 10. [PubMed:18784265]
  3. Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjoqvist F, Ingelman-Sundberg M: Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol. 1994 Sep;46(3):452-9. [PubMed:7935325]
  4. Leathart JB, London SJ, Steward A, Adams JD, Idle JR, Daly AK: CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles. Pharmacogenetics. 1998 Dec;8(6):529-41. [PubMed:9918137]
  5. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]